Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV

PHASE4CompletedINTERVENTIONAL
Enrollment

840

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2013

Conditions
Peripheral Arterial Occlusive Disease
Interventions
DRUG

Alprostadil

"* Active Substance: Prostaglandin E1~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion"

OTHER

Placebo

"* Active Substance: Lactose~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion"

Trial Locations (78)

Unknown

404, Pilsen

414, Ústí nad Labem

1, Karlsbad

502, Aguascalientes

505, Mérida

501, Querétaro

306, Bydgoszcz

321, Gmina Końskie

320, Krakow

314, Lublin

315, Lublin

316, Poznan

317, Poznan

301, Szczecin

304, Szczecin

307, Warsaw

308, Warsaw

309, Warsaw

318, Warsaw

319, Warsaw

312, Wroclaw

322, Zamość

246, Barnaul

205, Chelyabinsk

244, Chelyabinsk

228, Irkutsk

242, Kazan'

227, Kemerovo

201, Moscow

202, Moscow

203, Moscow

209, Moscow

219, Moscow

220, Moscow

230, Moscow

248, Moscow

231, Novosibirsk

232, Novosibirsk

222, Omsk

217, Petrozavodsk

206, Rostov-on-Don

225, Rostov-on-Don

236, Rostov-on-Don

239, Rostov-on-Don

224, Ryazan

210, Saint Petersburg

212, Saint Petersburg

213, Saint Petersburg

214, Saint Petersburg

215, Saint Petersburg

216, Saint Petersburg

218, Samara

237, Saratov

243, Tula

234, Tver'

238, Tyumen

241, Ufa

240, Volgograd

221, Yaroslavl

223, Yekaterinburg

247, Yekaterinburg

112, Dnipropetrovsk

109, Donetsk

110, Donetsk

114, Ivano-Frankivsk

111, Kharkiv

101, Kiev

102, Kiev

103, Kiev

104, Kiev

105, Kiev

106, Lviv

118, Odesa

119, Odesa

113, Uzhhorod

116, Vinnytsia

107, Zaporizhzhya

108, Zaporizhzhya

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Aptiv Solutions

INDUSTRY

lead

UCB BIOSCIENCES GmbH

INDUSTRY

NCT00596752 - Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV | Biotech Hunter | Biotech Hunter